Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2312 • 2019 ACR/ARP Annual Meeting
Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture
Suguru Honda¹, Ryoko Sakai ², Masako Majima ¹, Naoko Konda ¹, Hideto Takada ¹, Kazuhiko Yamamoto ³, Tsutomu Takeuchi ⁴ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The risk of lymphoma is higher among patients with rheumatoid arthritis (RA) compared to general populations 1. Methotrexate (MTX), the anchor drug for RA,…
Abstract Number: 2330 • 2019 ACR/ARP Annual Meeting
Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis
Sicong Huang¹, Tianrun Cai ², Daniel Solomon ³, Zeling He ¹, Kumar Dahal ², Chuan Hong ⁴, Andrew Cagan ⁵, Seoyoung C. Kim ⁶, Jacob Joseph ⁷, Tianxi Cai ⁸ and Katherine Liao ², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁴Harvard Medical School, Boston, MA, ⁵Research Information Science and Computing, Partners Healthcare, Boston, ⁶Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁷Veterans Affairs Boston Healthcare System and Brigham and Women’s Hospital, Boston, MA, ⁸Harvard T.H. Chan School of Public Health, Boston
Background/Purpose: For patients with rheumatoid arthritis (RA), heart failure (HF) is a significant cause of morbidity and mortality. HF is further classified into 2 subtypes…
Abstract Number: 2351 • 2019 ACR/ARP Annual Meeting
Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Jeffrey Curtis¹, Yong Lin ², Karthinathan Thangavelu ³, Marina Stanislav ⁴, Gregory St John ⁵, Antonio Gómez-Centeno ⁶, Carlo Selmi ⁷, Thomas Huizinga ⁸, José Antonio Maldonado-Cocco ⁹, Marwan Bukhari ¹⁰ and Frank Buttgereit ¹¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Bridgewater, NJ, ³Sanofi Genzyme, Boston, MA, ⁴V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁷Humanitas Research Hospital, University of Milan, Milan, Italy, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Buenos Aires University School of Medicine, Buenos Aires, Argentina, ¹⁰Lancaster University Medical School, Lancaster, United Kingdom, ¹¹Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The EXTEND open-label extension study (NCT01146652) is collecting data on long-term treatment of RA with sarilumab as monotherapy and in combination with conventional synthetic…
Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
Abstract Number: 2408 • 2019 ACR/ARP Annual Meeting
A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis
Elizabeth Salt¹, Amanda Wiggins ², Kristine Lohr ² and Mary Kay Rayens ², ¹University of Kentucky, Lexington, KY, ²University of Kentucky, Lexington
Background/Purpose: Prior research suggests that medication decision-making in rheumatoid arthritis (RA) patients is affected by disease activity, satisfaction with care, trust in their health care…
Abstract Number: 2847 • 2019 ACR/ARP Annual Meeting
Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA
Paul Studenic¹, David Felson ², Maarten de Wit ³, Farideh Alasti ⁴, Tanja Stamm ¹, Josef Smolen ¹ and Daniel Aletaha ¹, ¹Medical University of Vienna, Vienna, Austria, ²Boston University School of Medicine, Department of Rheumatology, Boston, ³Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁴Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria
Background/Purpose: The patient global assessment (PGA) is a core set variable to assess RA disease activity. It is strongly linked to patient-reported pain and is…
Abstract Number: 53 • 2019 ACR/ARP Annual Meeting
Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis
Agathe Leblond ¹, Sonia Pezet ¹, Anne Cauvet ¹, Claudine Casas ¹, Julie Pires Da Silva ², Roxane Herve ³, Luca Semerano ⁴, Christophe Lemaire ⁵, Yannick Allanore ⁶ and Jerome Avouac⁶, ¹INSERM U1016, Paris, France, ²Paris Sud University, Chateany Malabry, France, ³Paris 13 University, Bobigny, France, ⁴INSERM UMR 1125 , Université Paris 13, Bobigny, France, ⁵Paris Sud University, Chatenay malabry, France, ⁶Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France
Background/Purpose: To decipher the phenotype of endothelial cells (ECs) derived from circulating progenitors issued from patients with rheumatoid arthritis (RA).Methods: Proliferation capacities between RA and…
Abstract Number: 185 • 2019 ACR/ARP Annual Meeting
Accrual of Multimorbidity After Incident Rheumatoid Arthritis and Matched Comparators Using a Large Prospective Cohort with 30 Years of Follow-up
Kazuki Yoshida¹, Tzu-Chieh Lin ², Melissa Y Wei ³, Susan Malspeis ¹, Su H. Chu ⁴, Carlos Camargo ⁵, Benjamin A. Raby ¹, Hyon K. Choi ⁵, Sara K. Tedeschi ⁶, Medha Barbhaiya ⁷, Bing Lu ¹, Karen Costenbader ¹, Elizabeth Karlson ¹ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Amgen, Thousand Oaks, CA, ³University of Michigan, Ann Arbor, MI, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) patients often suffer from multimorbidity, the coexistence of multiple chronic morbidities. However, little is known about how multimorbidity accrues over time…
Abstract Number: 261 • 2019 ACR/ARP Annual Meeting
Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample
Shraddha Jatwani¹, Karan Chugh ¹, Bikramjit Bindra ² and Karan Jatwani ³, ¹St. Vincent Evansville, Evansville, ²Government Medical College & Hospital, Chandigarh, India, ³Mount Sinai West - St Luke’s Hospital, New York
Background/Purpose: Atrial Fibrillation (AF) is a common cardiac arrhythmia related to increased cardiovascular morbidity and mortality. There is a significant association of systemic inflammation with…
Abstract Number: 444 • 2019 ACR/ARP Annual Meeting
Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration
Elena Myasoedova¹, Annette De Thurah ², Marie-Line Erpelding ³, Emilce Schneeberger ⁴, Thomas Maribo ⁵, Gustavo Citera ⁶, John Davis ¹, Eric Matteson ⁷, Cynthia Crowson ⁸, Bruno Fautrel ⁹ and Francis Guillemin ³, ¹Mayo Clinic, Rochester, MN, ²Aarhus University Hospital, Aarhus, Denmark, ³Inserm, University of Lorraine, Nancy, France, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵DEFACTUM, Aarhus, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ⁸Mayo Clinic Rochester, Rochester, ⁹Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: Flares are inherent to the rheumatoid arthritis (RA) disease course and associated with poor clinical outcomes including low quality of life, joint damage and…
Abstract Number: 469 • 2019 ACR/ARP Annual Meeting
Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis
Susumu Nishiyama¹, Tetsuji Sawada ² and Shigeto Tohma ³, ¹Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ²Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan, ³National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: To predict prognosis of patients with rheumatoid arthritis (RA) from the location and the size of affected joints.Methods: Data of 7,776 patients with RA,…
Abstract Number: 506 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
Bernard Combe¹, Alan Kivitz ², Yoshiya Tanaka ³, Désirée van der Heijde ⁴, Franziska Matzkies ⁵, Beatrix Bartok ⁵, Lei Ye ⁵, Ying Guo ⁵, Chantal Tasset ⁶, John Sundy ⁵, Neelufar Mozaffarian ⁵, Robert B.M. Landewé ⁷, Sang-Cheol Bae ⁸, Edward Keystone ⁹ and Peter Nash ¹⁰, ¹CHU Montpellier, Montpellier University, Montpellier, France, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Amsterdam University Medical Center, Amsterdam, Netherlands, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Filgotinib (FIL) is an orally administered, potent and selective inhibitor of Janus kinase 1 (JAK1) that has shown good efficacy and was well tolerated…
Abstract Number: 641 • 2019 ACR/ARP Annual Meeting
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Anders Bengtsson ¹, Helena Tyden ¹, Tiffany Pan ², J. Lee Nelson ³ and Christian Lood², ¹Lund University, Lund, Sweden, ²University of Washington, Seattle, ³Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Circulating immune complexes (IC) are detectable in a variety of systemic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), reflecting the…
Abstract Number: 924 • 2019 ACR/ARP Annual Meeting
Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance
Background/Purpose: We recently reported that highly-sensitive cardiac troponin-I (hs-cTnI) associates with occult coronary atherosclerosis burden and cardiovascular event (CVE) risk in rheumatoid arthritis (RA). We…
Abstract Number: 1123 • 2019 ACR/ARP Annual Meeting
Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics
Maria Schletzbaum¹, Xing Wang ¹, Robert Greenlee ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Marshfield Clinic Research Institute, Marshfield, WI
Background/Purpose: Smoking doubles the risk of developing RA, and continuing to smoke after RA diagnosis is associated with worse disease control, treatment failure, and premature…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].